Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
Myriad Genetics (NASDAQ: MYGN) has scheduled its fourth quarter and full year 2024 earnings release for February 24, 2025, after market close, with a conference call at 4:30 pm ET the same day. During the call, management will discuss the company's financial performance and provide a business update.
The company has also announced participation in three upcoming healthcare investor conferences in March 2025:
- TD Cowen 45th Annual Health Care Conference (March 4)
- Raymond James 46th Annual Institutional Investors Conference (March 4)
- Leerink Global Healthcare Conference (March 10)
Myriad Genetics (NASDAQ: MYGN) ha programmato il rilascio dei risultati del quarto trimestre e dell'intero anno 2024 per il 24 febbraio 2025, dopo la chiusura del mercato, con una conference call alle 16:30 ET dello stesso giorno. Durante la chiamata, la direzione discuterà le performance finanziarie dell'azienda e fornirà un aggiornamento sulle attività.
L'azienda ha anche annunciato la partecipazione a tre conferenze per investitori nel settore sanitario in programma per marzo 2025:
- 45ª Conferenza Annuale sulla Salute TD Cowen (4 marzo)
- 46ª Conferenza Annuale per Investitori Istituzionali Raymond James (4 marzo)
- Conferenza Globale sulla Salute Leerink (10 marzo)
Myriad Genetics (NASDAQ: MYGN) ha programado la publicación de sus resultados del cuarto trimestre y del año completo 2024 para el 24 de febrero de 2025, después del cierre del mercado, con una conferencia telefónica a las 4:30 p. m. ET el mismo día. Durante la llamada, la dirección discutirá el rendimiento financiero de la empresa y proporcionará una actualización del negocio.
La empresa también ha anunciado su participación en tres próximas conferencias de inversores en el sector salud en marzo de 2025:
- 45ª Conferencia Anual de Salud TD Cowen (4 de marzo)
- 46ª Conferencia Anual de Inversores Institucionales Raymond James (4 de marzo)
- Conferencia Global de Salud Leerink (10 de marzo)
Myriad Genetics (NASDAQ: MYGN)는 2025년 2월 24일 장 마감 후 2024년 4분기 및 연간 실적 발표를 예정하고 있으며, 같은 날 오후 4시 30분 ET에 컨퍼런스 콜을 진행할 예정입니다. 이 전화 회의에서 경영진은 회사의 재무 성과에 대해 논의하고 비즈니스 업데이트를 제공할 것입니다.
회사는 또한 2025년 3월에 열리는 세 가지 헬스케어 투자자 회의에 참여할 것이라고 발표했습니다:
- TD Cowen 제45회 연례 헬스케어 회의 (3월 4일)
- Raymond James 제46회 연례 기관 투자자 회의 (3월 4일)
- Leerink 글로벌 헬스케어 회의 (3월 10일)
Myriad Genetics (NASDAQ: MYGN) a prévu la publication de ses résultats du quatrième trimestre et de l'année 2024 pour le 24 février 2025, après la clôture du marché, avec une conférence téléphonique à 16h30 ET le même jour. Lors de cet appel, la direction discutera de la performance financière de l'entreprise et fournira une mise à jour sur les activités.
L'entreprise a également annoncé sa participation à trois prochaines conférences pour investisseurs dans le secteur de la santé en mars 2025 :
- 45e Conférence Annuelle sur la Santé de TD Cowen (4 mars)
- 46e Conférence Annuelle pour Investisseurs Institutionnels de Raymond James (4 mars)
- Conférence Mondiale sur la Santé de Leerink (10 mars)
Myriad Genetics (NASDAQ: MYGN) hat die Veröffentlichung der Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 24. Februar 2025 nach Börsenschluss angesetzt, mit einer Telefonkonferenz um 16:30 Uhr ET am selben Tag. Während des Anrufs wird das Management die finanzielle Leistung des Unternehmens erörtern und ein Update zum Geschäft geben.
Das Unternehmen hat außerdem die Teilnahme an drei bevorstehenden Investorenkonferenzen im Gesundheitswesen im März 2025 angekündigt:
- 45. Jährliche Gesundheitskonferenz von TD Cowen (4. März)
- 46. Jährliche Konferenz für institutionelle Investoren von Raymond James (4. März)
- Leerink Global Healthcare Conference (10. März)
- None.
- None.
Management will participate in three upcoming investor healthcare conferences
SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2024.
A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.
Upcoming Investor Conferences
Management plans to participate in the following investor healthcare conferences:
- The TD Cowen 45th Annual Health Care Conference – fireside chat at 9:50 am ET on Tuesday, March 4, 2025.
- The Raymond James 46th Annual Institutional Investors Conference – formal presentation at 4:00 pm ET on Tuesday, March 4, 2025.
- The Leerink Global Healthcare Conference – fireside chat at 2:20 pm ET on Monday, March 10, 2025.
About Myriad Genetics
Myriad Genetics is a leading genetic and genomic tumor testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
When will Myriad Genetics (MYGN) release Q4 and full year 2024 earnings?
Which investor conferences will MYGN attend in March 2025?
How can investors access MYGN's Q4 2024 earnings call?
Will MYGN's Q4 2024 earnings call be available for replay?
